Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis

Stock Information for Sigyn Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sigyn Therapeutics Inc.

Sigyn Therapeutics(TM) to Present at Tomorrow's Emerging Growth Conference
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
Sigyn Therapeutics(TM) Announces Filing of 2023 Annual Report on SEC Form 10-K
Sigyn Therapeutics Releases Letter to Shareholders
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
Sigyn Therapeutics(TM) Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
Sigyn Therapeutics to Present at Today's Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.